1083-41-6

Usage

Uses

Used in Food Industry:
Butyl gallate is used as an antioxidant and preservative for preventing the oxidation of fats and oils, which can lead to rancidity and spoilage in food products. Its ability to extend the shelf life and maintain the quality of food items makes it a popular choice in the food industry.
Used in Cosmetics Industry:
In the cosmetics industry, butyl gallate is used as a preservative to maintain the quality and stability of cosmetic products. It inhibits the degradation of ingredients, ensuring the longevity and effectiveness of cosmetics.
Used in Pharmaceuticals Industry:
Butyl gallate is also utilized in the pharmaceuticals industry as an antioxidant and preservative. It helps maintain the stability and quality of pharmaceutical products, ensuring their safety and efficacy.
However, it is important to note that there are some concerns about potential health risks associated with butyl gallate, and its use in certain applications is regulated by authorities to ensure safe levels of exposure.

InChI:InChI=1/C11H14O5/c1-2-3-4-16-11(15)7-5-8(12)10(14)9(13)6-7/h5-6,12-14H,2-4H2,1H3

Upstream product

• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 71-36-3 butan-1-ol 
• 1486-48-2 3,4,5-tribenzyloxybenzoic acid 

Downstream Products

• 108853-29-8 n-butyl 3,4-dihydroxy-5-methoxybenzoate 
• 1034-01-1 Octyl gallate 
• 1329454-97-8 butyl 3-O-(β-D-glucopyranosyluronate)-4,5-dihydroxybenzoate 
• 1329454-74-1 butyl 3-O-(β-D-glucopyranosyl)-4,5-dihydroxybenzoate 
• 1329454-92-3 butyl 3-O-(methyl-2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-4,5-dihydroxybenzoate 
• 1329454-63-8 butyl 3-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside)-4,5-dihydroxybenzoate 
• 944730-07-8 (E)-6-(4-(benzyloxy)-3-methoxystyryl)-4-methoxybenzo[d][1,3]dioxole 
• 22934-59-4 (7-methoxybenzo[d][1,3]dioxol-5-yl)methanol 
• 5780-07-4 3-methoxy-4,5-methylenedioxybenzaldehyde 

Related news

Encapsulation and solubilization of the antioxidants gallic acid and ethyl, propyl and BUTYL GALLATE (cas 1083-41-6) with β-cyclodextrin08/12/2019

We investigated the formation of inclusion complexes of the antioxidants (AOs) gallic acid, GA, and its hydrophobic derivatives ethyl (EG), propyl (PG) and butyl (BG) gallate with β-cyclodextrin (β-CD) by employing the UV spectral shifts method and, for the sake of comparisons, a modified phas...detailed

Relevant academic research and scientific papers

Microwave-assisted esterification of gallic acid

An efficient synthesis of alkyl gallates under microwave irradiation was described. The reaction took place in 6-10 mins, which was much shorter than the traditional synthetic methods, with almost quantitative yields.

Suppression of TNF-α induced NFκB activity by gallic acid and its semi-synthetic esters: Possible role in cancer chemoprevention

Gallic acid (3,4,5-trihydroxybenzoic acid), found in many plants either in free-form or part of tannins, is known to possess anti-microbial, antioxidant and cytotoxic properties. NFκB regulates the expression of several genes involved in carcinogenesis. These include anti-apoptotic, cytokines and cell cycle-regulatory genes. It is well established that the transcriptional factor NFκB is deregulated in many forms of cancer. Thus, agents that can suppress NFκB activation have the potential of suppressing carcinogenesis. In the present investigation, gallic acid was isolated from Alchornea glandulosa (Euphorbiaceae) and eight esters were synthesised. These compounds were evaluated against TNF-α-induced NFκB activation with stably transfected 293/NFκB-Luc human embryonic kidney cells. Gallates with IC50 values in a range of 10-56 M mediated inhibitory activity higher than gallic acid (IC50 76.0 4.9 M). In addition to inhibiting NFκB activation, gallic acid mediated a modest cytotoxic effect, and some of the gallates affected cell viability at the tested concentrations. Based on these results, suppression of NFκB activation by gallate esters could play a chemopreventive role in carcinogenesis.

A preparation method of electronic grade gallic octyl ester

The present invention provides a kind of electronic grade gallic octyl ester of preparation method, which belongs to the technical field of organic synthesis. The gallic acid dissolved in alcohol, then drop adds the chlorination [...], then adding aromatic hydrocarbon solvent, a catalytic amount of B (C6F5) 3 and octanol, moiety will be distillation after the exchange, getting the gallic octyl ester. This method avoids the use of heavy metal catalyst, high yield, low cost, and is suitable for industrial scale production, the ester exchange after the end of the added metal ion adsorbent after the metal ion adsorption, distillation electronic level of gallic octyl ester.

Synthesis and evaluation of novel benzotropolones as Atg4B inhibiting autophagy blockers

Autophagy is an intracellular degradation/recycling pathway that provides nutrients and building blocks to cellular metabolism and keeps the cytoplasm clear of obsolete proteins and organelles. During recent years, dysregulated autophagy activity has been reported to be a characteristic of many different disease types, including cancer and neurodegenerative disorders. This has created a strong case for development of autophagy modulating compounds as potential treatments for these diseases. Inhibitors of autophagy have been proposed as a therapeutic intervention in, e.g., advanced cancer, and inhibiting the cysteine protease Atg4B has been put forward as a main strategy to block autophagy. We recently identified and demonstrated -both in vitro and in vivo - that compounds with a benzotropolone basic structure targeting Atg4B, can significantly slow down tumor growth and potentiate the effect of classical chemotherapy. In this study we report the synthesis and inhibition profile of new benzotropolone derivatives with additional structural modifications at 6 different positions. To obtain a solid inhibition profile, all compounds were evaluated on three levels, including two cell-based assays to confirm autophagy and intracellular Atg4B inhibition and an SDS-PAGE-based experiment to assess in vitro Atg4B affinity. Several molecules with a promising profile were identified.

Synthesis and in vitro antimalarial activity of alkyl esters of gallate as a growth inhibitor of plasmodium falciparum

This study is aimed to synthesize alkyl esters gallate and determine its in vitro antimalarial activity against parasite Plasmodium falciparum. Fourteen compounds of alkyl esters gallate were synthesized by esterification of the carboxyl group of gallic acid with a series of alkyl alcohols, as well as methoxylation of the hydroxy groups on the aromatic ring of gallic acid. Antimalarial activity of the synthesized alkyl esters gallate were expressed by IC50 value, with gallic acid as an original compound and artemisin as a positive control. Compared to gallic acid, eleven synthesized compounds of alkyl esters gallate, have a greater antimalarial activity against Plasmodium falciparum. On the other hand, three compounds, that are propyl gallate, butyl gallate and trimethoxy methyl gallate, showed a lower antimalarial activity. Moreover, compared to gallic acid (IC50: 194.86 mM) and artemisin (IC50: 0.5 mM), two synthesized compounds of alkyl gallates, namely methyl gallate and hexyl gallate exhibited the stronger antimalarial activity against Plasmodium falciparum, with IC50 value of 0.03 mM and 0.11 mM, respectively. Our result clearly demonstrated that methyl gallate and hexyl gallate as a promising candidate for the new antimalarial agents.

Disconnecting the Estrogen Receptor Binding Properties and Antimicrobial Properties of Parabens through 3,5-Substitution

Commercially utilized parabens are employed for their antimicrobial properties, but a weak binding to the estrogen receptor alpha (ERα) may lead to breast cancer in some applications. Modification of the paraben scaffold should allow for a disconnection of these observed properties. Toward this goal, various 3,5-substituted parabens were synthesized and assessed for antimicrobial properties against S. aureus as well as competitive binding to the ERα. The minimum inhibitory concentration assay confirmed retention of antimicrobial activity in many of these derivatives, while all compounds exhibited decreased xenoestrogen activity as determined by a combination of competitive enzyme linked immunosorbent assay (ELISA), proliferation, and estrogen receptor binding assay. Thus, these changes to the paraben scaffold have led to a multitude of paraben derivatives with antimicrobial properties up to 16 times more active than the parent paraben and that are devoid or significantly diminished of potential breast cancer causing properties.

HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS

The present invention relates to compounds having a benzotropolone core, and compositions containing said compounds acting as ATG4B inhibitors, thereby inhibiting autophagy. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.

Synthetic method of gallic acid lower alkanol ester

A synthetic method of gallic acid lower alkanol ester comprises the following steps of: (1) placing gallic acid and lower alkanol in a reactor, adding a sulfonic acid resin catalyst subjected to hydrophobic modification, carrying out stirring, heating to a temperature of 65 to 120 DEG C, performing the reaction for 4 to 10h and filtering to obtain filtrate; (2) removing excessive alcohol in the filtrate by evaporation so as to obtain a crude product, then carrying out recrystallization by deionized water, and carrying out suction filtration and drying to obtain the gallic acid lower alkanol ester. The synthetic method disclosed by the invention is simple, is safe to operate; yield of the gallic acid lower alkanol ester is greater than or equal to 92 percent; product purity is more than or equal to 99.5 percent; moreover, the catalyst has excellent performance; the water distribution link in a conventional method is reduced; a reaction apparatus is simplified; the synthetic method has good repeatability.

Active component having synergistic effect together with hyperuricemia treatment medicine, and febuxostat composition of active component

The invention discloses an active component having a synergistic effect together with a hyperuricemia treatment medicine. The active component is plant polyphenol with the structure represented by formula (I) and a pharmaceutically acceptable salt of the plant polyphenol. The invention also provides a febuxostat composition. The febuxostat composition comprises febuxostat and the active component having a synergistic effect together with the hyperuricemia treatment medicine. The active component having a synergistic effect together with the hyperuricemia treatment medicine, and acts together with the hyperuricemia treatment medicine in the prior art in order to reduce the toxic and side effects of the hyperuricemia treatment medicine and keep an ideal uric acid reduction effect, and the active component has a synergistic medicine effect in the treatment process of hyperuricemia and hyperuricemia induced gouts or gout complications.

Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors

Linear and branched compounds that contain two, three or five units of galloyl (3,4,5-trihydroxybenzoyl) or its isomer 2,3,4-trihydroxybenzoyl, as well as other mono- or dihydroxybenzoyl moieties have been synthesized. These molecules have been evaluated for their in vitro inhibitory effects against a wide panel of viruses showing preferential activity against HIV and HCV. Our structure-activity relationship studies demonstrated that the 2,3,4-trihydroxybenzoyl moiety provides better antiviral activities than the galloyl (3,4,5-trihydroxybenzoyl) moiety that is present in natural green tea catechins. This observation can be of interest for the further rational exploration of compounds with anti-HCV/HIV properties. The most notable finding with respect to HIV is that the tripodal compounds 43 and 45, with three 2,3,4-trihydroxybenzoyl moieties, showed higher activities than linear compounds with only one or two. With respect to HCV, the linear compounds, 52 and 41, containing a 12 polymethylene chain and two 2,3 di- or 2,3,4 tri-hydroxybenzoyl groups respectively at the ends of the molecule showed good antiviral efficiency. Furthermore, the anti-HCV activity of both compounds was observed at concentrations well below the cytotoxicity threshold. A representative member of these compounds, 41, showed that the anti-HCV activity was largely independent of the genetic make-up of the HCV subgenomic replicon and cell lines used.